Company / R&D per Share
Spyre Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.85
FY2025
5-year range
$1.19 / $34.24
FY2021-FY2025
Trend
-36.9%
vs FY2024
Sector context
#76 of 208
Health Care
What the data says
At $2.85, Spyre Therapeutics, Inc.'s r&d per share ranks #76 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.95 in FY2019 to $34.24 in FY2023.
Based on SEC 10-K filings.
2.85 in FY2025 with a 5-year CAGR of +17.7%.
Declined from $34.24 to $2.85 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +33.1%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Sector benchmark
#76 of 208 in Health CareTop 37% of 208This company $2.85 Sector average $28.82
▼
-90.1% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 36.9% year-over-year.
- Ranks #76 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.85 | -36.9% |
| FY2024 | $4.51 | -86.8% |
| FY2023 | $34.24 | +2733.6% |
| FY2022 | $1.21 | +1.5% |
| FY2021 | $1.19 | -5.7% |
| FY2020 | $1.26 | +33.6% |
| FY2019 | $0.95 | -13.2% |
| FY2018 | $1.09 | -27.8% |
| FY2017 | $1.51 | -18.6% |
| FY2016 | $1.85 | -90.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026